Hypertrophic cardiomyopathy (HCM)
Conditions
Interventions
HCM cohort (single-arm):None
Sponsors
Peking Union Medical College Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Confirmed hypertrophic cardiomyopathy: A maximal left ventricular wall thickness = 15 mm in any segment (= 13 mm in patients with a positive family history) on echocardiography or cardiac magnetic resonance imaging, not solely explained by abnormal loading conditions (e.g., hypertension or aortic stenosis). 2.Adherence: Willing to wear the monitoring device for continuous 14–28-day baseline monitoring and to provide a blood sample. 3.Informed consent: Signed written informed consent, with agreement to complete the 3-year follow-up. 4.Age: 18 - 80 years old.
Exclusion criteria
Exclusion criteria: 1.Limited life expectancy: Advanced malignancy or other severe systemic disease with a life expectancy < 1 year. 2.End-stage disease: Baseline NYHA class IV, or already listed for cardiac transplantation (precluding observation of "progression"). 3.Contraindication to or inability to use the device: Bilateral upper-limb disability preventing watch wear, or severe cognitive impairment preventing device operation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Major composite heart failure endpoint (time to first composite event); | — |
Secondary
| Measure | Time frame |
|---|---|
| Arrhythmic events;Biochemical progression of NT-proBNP;All-cause mortality;Functional deterioration (NYHA class); | — |
Countries
China
Contacts
Public ContactZhuang Tian
Peking Union Medical College Hospital
Outcome results
None listed